Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrothyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 0.97 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 0.97 |
| ▸ | MEN1 | O00255 | 7/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | PPARG | P37231 | 5/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
| ▸ | USP2 | O75604 | 3/20 | 0.97 |
| ▸ | TTR | P02766 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.97 |
| ▸ | RXRA | P19793 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thyroxine SCHEMBL2014581 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL1997042 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL269164 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL1995241 | 1.00 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL3421376 | 0.99 | THRB (0.95) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL23098 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL4997979 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL4575383 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL11131863 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL30885760 | 0.99 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | claimed |
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9023889-B2 | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| CN-102458543-A | Dry powder inhalers | 3M INNOVATIVE PROPERTIES CO | 2012-05-16 | — | — | CN | disclosed |
| US-7914893-B2 | Particles comprising an anion-binding layer containing anion-forming organic active compounds, and method of making and using thereof | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20100167936-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | MERCK PATENT GESELLSCHAFT (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-0108403-A2 | Substituted carboxyfluoresceins | ABBOTT LABORATORIES (US) | 1984-05-16 | — | — | EP | disclosed |
| EP-0108400-A2 | Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques | ABBOTT LABORATORIES (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4217429-A | FROM DIHYDROOXAZINES | MERCK & CO., INC. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4206295-A | Process of preparing poly[{alkyl-(3-ammoniopropyl)iminio}trimethylene dihalides] | MERCK & CO., INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4205064-A | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] | MERCK & CO., INC. (US) | 1980-05-27 | — | — | US | disclosed |
| US-4161581-A | Poly-[(dialkyl and hydroxy-dialkyl-imino)ethylene halides] and process | MERCK & CO., INC. (US) | 1979-07-17 | — | — | US | disclosed |
| US-4156693-A | HYDROXYPROPYLATION WITH OXETANE, SALT FORMATION WITH HYDROHALIDE, CHLORINATION WITH THIONYL CHLORIDE | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4098726-A | MICROBIOCIDES, FLOCCULANTS, ANTISTATIC AND CHELATING AGENTS | MERCK & CO., INC. (US) | 1978-07-04 | — | — | US | disclosed |
| US-4027009-A | QUATERNARY POLY(ALKYLIMINO)ALKYLENE AS BILE ACID BINDERS | MERCK & CO., INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-4016209-A | 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium halide and acid addition salts thereof | MERCK & CO., INC. (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100167936-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | PROC, TTPA, COX6C | THRB 4156/4885THRA 1689/4885MEN1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.